Precision Psychiatry Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 1.27 Billion
CAGR (2026-2031)	14.95%
Fastest Growing Segment	Genetic
Largest Market	North America
Market Size (2031)	USD 2.93 Billion

Market Overview

The Global Precision Psychiatry Market will grow from USD 1.27 Billion in 2025 to USD 2.93 Billion by 2031 at a 14.95% CAGR. Precision psychiatry is a medical approach that integrates individual biological data, such as genetic and metabolic biomarkers, with clinical information to tailor mental health treatments to specific patient characteristics. The primary drivers facilitating the growth of this market include the escalating global prevalence of complex mental disorders and the rapid maturity of genomic sequencing technologies which allow for more accurate patient stratification. This trajectory is further supported by a surge in research and development activities aimed at discovering novel therapeutic targets. According to the Pharmaceutical Research and Manufacturers of America, in 2025, there were over 160 promising mental health treatments in development, illustrating the substantial industrial commitment to advancing personalized therapeutic options.

Despite these advancements, the market encounters a significant challenge regarding the high capital investment required for integrating these precision tools into existing healthcare infrastructures. The exorbitant costs associated with genetic profiling and data analysis may limit accessibility and delay the widespread adoption of precision psychiatry solutions, particularly in resource-constrained healthcare systems.

Key Market Drivers

The Integration of Artificial Intelligence and Machine Learning in Diagnostics is fundamentally reshaping the Global Precision Psychiatry Market by enabling the analysis of vast datasets to identify patient-specific therapeutic responses. These technologies facilitate the synthesis of genomic, transcriptomic, and clinical data, allowing providers to move beyond subjective symptom-based diagnoses toward biologically validated treatment protocols. This technological surge is evidenced by the rapid commercial expansion of AI-enabled precision medicine platforms that support personalized care pathways. According to Tempus AI, August 2025, in the 'Second Quarter 2025 Results' report, the company achieved a revenue increase of 89.6% year-over-year to $314.6 million, driven largely by the robust adoption of its genomics and data services.

Concurrently, the Increasing Clinical Adoption of Pharmacogenomic Testing is driving market growth as clinicians seek to optimize medication selection and minimize adverse drug reactions. This shift is critical given the magnitude of the crisis; according to the World Health Organization, in 2025, more than 1 billion people worldwide were living with a mental disorder, underscoring the urgent need for more effective, targeted interventions. By analyzing genetic variations that affect drug metabolism, pharmacogenomic tests reduce the inefficiency of trial-and-error prescribing. Despite reimbursement challenges in some regions, utilization remains resilient. According to Myriad Genetics, November 2025, in the 'Third Quarter 2025 Financial Results' report, test volume for its GeneSight psychotropic pharmacogenomic test grew 8% year-over-year, reflecting sustained demand for personalized mental health insights.

Download Free Sample Report

Key Market Challenges

The high capital investment required for integrating precision psychiatry tools constitutes a substantial impediment to the market's expansion. Precision psychiatry relies heavily on advanced genomic sequencing and complex data analysis to tailor treatments, both of which necessitate expensive technological infrastructure and specialized personnel. These substantial costs create a high barrier to entry, particularly for healthcare providers in developing regions or those operating within publicly funded systems with limited budgets. Consequently, the adoption of these personalized solutions is often restricted to well-funded private institutions, thereby fragmenting the global market and limiting the scalable reach of these innovations.

This financial disparity is significantly exacerbated by the severe underfunding of mental healthcare systems globally. According to the World Health Organization, in 2025, median government spending on mental health remained stagnant at merely 2% of total health budgets, indicating a critical lack of financial infrastructure to support advanced medical integration. This chronic underinvestment directly hampers the ability of healthcare systems to procure and maintain the sophisticated diagnostic tools required for precision psychiatry, ultimately decelerating the overall growth of the market and preventing the widespread application of personalized therapeutic strategies.

Key Market Trends

The Application of Precision Medicine Frameworks to Psychedelic Therapeutics is revolutionizing treatment paradigms by shifting focus from broad-spectrum administration to biomarker-guided protocols. This trend involves leveraging genetic and neurophysiological data to identify patients most likely to respond to potent compounds like psilocybin and novel neuroplastogens, thereby maximizing efficacy while mitigating safety risks associated with hallucinogenic effects. The industrial validation of this targeted approach is evident in major high-value deals within the sector, as biopharmaceutical entities seek to secure assets that couple potent mechanisms with precise patient stratification. According to Fierce Biotech, August 2025, AbbVie entered a definitive agreement to acquire Gilgamesh Pharmaceuticals’ precision psychedelic program for up to $1.2 billion, underscoring the significant commercial confidence in developing next-generation psychiatric assets with optimized pharmacological profiles.

Simultaneously, the Proliferation of Digital Phenotyping via Wearables and Mobile Devices is establishing a new standard for continuous, objective patient monitoring. By utilizing sensors in smartphones and smartwatches, clinicians can now capture real-time behavioral data—such as sleep patterns, physical activity, and social interaction—to construct detailed digital phenotypes that complement traditional clinical assessments. This integration of longitudinal real-world data allows for the early detection of symptomatic relapse and the refinement of personalized treatment plans beyond the clinical setting. The commitment to this data-driven methodology is reflected in the sustained funding of specialized firms; according to Alto Neuroscience, November 2025, in the 'Third Quarter 2025 Financial Results' report, the company maintained a cash position of $138.3 million to advance its precision psychiatry platform, which actively incorporates wearable metrics to de-risk clinical development.

Segmental Insights

The genetic segment currently stands as the fastest-growing category within the global precision psychiatry market, driven by the increasing integration of pharmacogenomics into clinical practice. This rapid expansion is primarily attributed to the ability of genetic testing to analyze metabolic variations, which assists clinicians in selecting appropriate medications and reducing the prevalence of adverse drug reactions. Furthermore, the validation of specific gene-drug interactions by regulatory authorities such as the US Food and Drug Administration has significantly enhanced provider confidence in these diagnostic tools. Consequently, healthcare institutions are prioritizing genetic profiling to minimize the trial-and-error phase often associated with treating mental health disorders.

Regional Insights

North America holds the leading position in the global precision psychiatry market, driven by extensive investments in mental health research and a strong concentration of key industry players. The region benefits from an established healthcare infrastructure and favorable reimbursement policies that encourage the adoption of personalized treatment solutions. Support from institutions like the National Institutes of Health accelerates genomic studies essential for developing targeted therapies. Furthermore, the U.S. Food and Drug Administration supports market expansion by establishing clear regulatory frameworks for pharmacogenomic testing and digital health applications, thereby reinforcing regional dominance.

Recent Developments

In October 2024, Alto Neuroscience reported topline results from a Phase 2b clinical trial evaluating its candidate ALTO-100 for the treatment of major depressive disorder. The study utilized a precision psychiatry approach by enriching the patient population with a specific memory-based cognitive biomarker. The company announced that the trial did not meet its primary endpoint, as the treatment failed to demonstrate a statistically significant improvement in depressive symptoms compared to placebo. Despite the efficacy outcome, the Chief Medical Officer noted that the drug maintained a favorable safety profile and that the company would continue to analyze the data to inform future biomarker-based development.
In October 2024, Boehringer Ingelheim entered into a strategic collaboration with the Center for Technology and Behavioral Health at Dartmouth College to advance the development of prescription digital therapeutics for serious mental illness. This partnership aimed to combine the pharmaceutical company's industry expertise with the academic center's pioneering research in digital health tools. The collaboration focused on creating and validating digital solutions that could complement pharmacological treatments for conditions such as schizophrenia. The initiative sought to deliver integrated, personalized care options to improve patient outcomes and address the growing global burden of mental health disorders.
In May 2024, Neumora Therapeutics initiated a Phase 2 clinical study to evaluate the safety and efficacy of its investigational drug, navacaprant, in patients with bipolar depression. The company described the drug as a potentially best-in-class kappa opioid receptor antagonist designed to modulate dopamine and reward processing pathways. This trial aimed to assess the therapy's ability to improve symptoms such as depressed mood and anhedonia in a patient population that often resists standard treatments. The initiation of this study marked a strategic expansion of the company’s precision neuroscience pipeline into broader mood disorder indications.
In March 2024, a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration had granted breakthrough therapy designation to its MM120 program for the treatment of generalized anxiety disorder. The organization also reported positive 12-week topline data from a Phase 2b clinical trial, which met its key secondary endpoint by demonstrating clinically and statistically significant durability of activity. The Chief Executive Officer stated that this regulatory designation and the accompanying data validated the potential of the treatment to address the substantial unmet medical needs of patients living with generalized anxiety disorder.

Key Market Players

Johnson & Johnson Services, Inc.
Roche Holding AG
Eli Lilly and Company
Pfizer Inc.
H. Lundbeck A/S
Helsinn Group
Takeda Pharmaceutical Company Limited
Otsuka Holdings Co., Ltd.
BioXcel Therapeutics, Inc.
Neurocrine Biosciences, Inc.

By Biomarkers	By Sample	By Technology	By Application	By End User	By Region
Genetic v/s Protein	Blood Based v/s Non-Blood-Based	Sequencing Polymerase Chain Reaction Microarray Immunoassay Others	Alzheimer’s Disease Parkinson’s Disease Autism Depression Others	Hospital & Clinics Academic & Research Institutions Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Precision Psychiatry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Psychiatry Market, By Biomarkers:

Genetic v/s Protein

Precision Psychiatry Market, By Sample:

Blood Based v/s Non-Blood-Based

Precision Psychiatry Market, By Technology:

Sequencing
Polymerase Chain Reaction
Microarray
Immunoassay
Others

Precision Psychiatry Market, By Application:

Alzheimer’s Disease
Parkinson’s Disease
Autism
Depression
Others

Precision Psychiatry Market, By End User:

Hospital & Clinics
Academic & Research Institutions
Others

Precision Psychiatry Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Psychiatry Market.

Available Customizations:

Global Precision Psychiatry Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Precision Psychiatry Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Psychiatry Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Biomarkers (Genetic v/s Protein)

5.2.2. By Sample (Blood Based v/s Non-Blood-Based)

5.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)

5.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism, Depression, Others)

5.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. North America Precision Psychiatry Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Biomarkers

6.2.2. By Sample

6.2.3. By Technology

6.2.4. By Application

6.2.5. By End User

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Precision Psychiatry Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Biomarkers

6.3.1.2.2. By Sample

6.3.1.2.3. By Technology

6.3.1.2.4. By Application

6.3.1.2.5. By End User

6.3.2. Canada Precision Psychiatry Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Biomarkers

6.3.2.2.2. By Sample

6.3.2.2.3. By Technology

6.3.2.2.4. By Application

6.3.2.2.5. By End User

6.3.3. Mexico Precision Psychiatry Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Biomarkers

6.3.3.2.2. By Sample

6.3.3.2.3. By Technology

6.3.3.2.4. By Application

6.3.3.2.5. By End User

7. Europe Precision Psychiatry Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Biomarkers

7.2.2. By Sample

7.2.3. By Technology

7.2.4. By Application

7.2.5. By End User

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Precision Psychiatry Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Biomarkers

7.3.1.2.2. By Sample

7.3.1.2.3. By Technology

7.3.1.2.4. By Application

7.3.1.2.5. By End User

7.3.2. France Precision Psychiatry Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Biomarkers

7.3.2.2.2. By Sample

7.3.2.2.3. By Technology

7.3.2.2.4. By Application

7.3.2.2.5. By End User

7.3.3. United Kingdom Precision Psychiatry Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Biomarkers

7.3.3.2.2. By Sample

7.3.3.2.3. By Technology

7.3.3.2.4. By Application

7.3.3.2.5. By End User

7.3.4. Italy Precision Psychiatry Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Biomarkers

7.3.4.2.2. By Sample

7.3.4.2.3. By Technology

7.3.4.2.4. By Application

7.3.4.2.5. By End User

7.3.5. Spain Precision Psychiatry Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Biomarkers

7.3.5.2.2. By Sample

7.3.5.2.3. By Technology

7.3.5.2.4. By Application

7.3.5.2.5. By End User

8. Asia Pacific Precision Psychiatry Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Biomarkers

8.2.2. By Sample

8.2.3. By Technology

8.2.4. By Application

8.2.5. By End User

8.2.6. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Precision Psychiatry Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Biomarkers

8.3.1.2.2. By Sample

8.3.1.2.3. By Technology

8.3.1.2.4. By Application

8.3.1.2.5. By End User

8.3.2. India Precision Psychiatry Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Biomarkers

8.3.2.2.2. By Sample

8.3.2.2.3. By Technology

8.3.2.2.4. By Application

8.3.2.2.5. By End User

8.3.3. Japan Precision Psychiatry Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Biomarkers

8.3.3.2.2. By Sample

8.3.3.2.3. By Technology

8.3.3.2.4. By Application

8.3.3.2.5. By End User

8.3.4. South Korea Precision Psychiatry Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Biomarkers

8.3.4.2.2. By Sample

8.3.4.2.3. By Technology

8.3.4.2.4. By Application

8.3.4.2.5. By End User

8.3.5. Australia Precision Psychiatry Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Biomarkers

8.3.5.2.2. By Sample

8.3.5.2.3. By Technology

8.3.5.2.4. By Application

8.3.5.2.5. By End User

9. Middle East & Africa Precision Psychiatry Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Biomarkers

9.2.2. By Sample

9.2.3. By Technology

9.2.4. By Application

9.2.5. By End User

9.2.6. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Precision Psychiatry Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Biomarkers

9.3.1.2.2. By Sample

9.3.1.2.3. By Technology

9.3.1.2.4. By Application

9.3.1.2.5. By End User

9.3.2. UAE Precision Psychiatry Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Biomarkers

9.3.2.2.2. By Sample

9.3.2.2.3. By Technology

9.3.2.2.4. By Application

9.3.2.2.5. By End User

9.3.3. South Africa Precision Psychiatry Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Biomarkers

9.3.3.2.2. By Sample

9.3.3.2.3. By Technology

9.3.3.2.4. By Application

9.3.3.2.5. By End User

10. South America Precision Psychiatry Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Biomarkers

10.2.2. By Sample

10.2.3. By Technology

10.2.4. By Application

10.2.5. By End User

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Precision Psychiatry Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Biomarkers

10.3.1.2.2. By Sample

10.3.1.2.3. By Technology

10.3.1.2.4. By Application

10.3.1.2.5. By End User

10.3.2. Colombia Precision Psychiatry Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Biomarkers

10.3.2.2.2. By Sample

10.3.2.2.3. By Technology

10.3.2.2.4. By Application

10.3.2.2.5. By End User

10.3.3. Argentina Precision Psychiatry Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Biomarkers

10.3.3.2.2. By Sample

10.3.3.2.3. By Technology

10.3.3.2.4. By Application

10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Precision Psychiatry Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Johnson & Johnson Services, Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Roche Holding AG

15.3. Eli Lilly and Company

15.4. Pfizer Inc.

15.5. H. Lundbeck A/S

15.6. Helsinn Group

15.7. Takeda Pharmaceutical Company Limited

15.8. Otsuka Holdings Co., Ltd.

15.9. BioXcel Therapeutics, Inc.

15.10. Neurocrine Biosciences, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Precision Psychiatry Market in 2025?

Which is the dominating region in the Global Precision Psychiatry Market?

Which is the fastest growing segment in the Global Precision Psychiatry Market?

What is the expected growth rate of the Global Precision Psychiatry Market?